The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

A Case of Pulmonary Alveolar Proteinosis that Improved with GM-CSF Inhalation Therapy

GM-CSF 흡입치료로 호전된 폐포단백증 1예

  • Chang, Bok-Soon (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Noh, Jung-Won (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ok, Chang-Soo (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Lee, Ga-Yeon (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Sohn, Seo-Young (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Bahng, Sun-Ha (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Chung, Man-Pyo (Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 장복순 (성균관대학교 의과대학 삼성서울병원 내과) ;
  • 노정원 (성균관대학교 의과대학 삼성서울병원 내과) ;
  • 옥창수 (성균관대학교 의과대학 삼성서울병원 내과) ;
  • 이가연 (성균관대학교 의과대학 삼성서울병원 내과) ;
  • 손서영 (성균관대학교 의과대학 삼성서울병원 내과) ;
  • 방선하 (성균관대학교 의과대학 삼성서울병원 내과) ;
  • 정만표 (성균관대학교 의과대학 삼성서울병원 내과)
  • Published : 2011.05.01
⟨ Previous Next ⟩

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare condition that is treated using whole lung lavage. A recent study suggested thatgranulocyte-macrophage colony stimulating factor (GM-CSF) plays roles in both the pathogenesis and treatment of PAP. Wepresent a 69-year-old man with PAP who deteriorated despite bilateral whole lung lavage; that said, his symptoms, chest X-rayfindings, and pulmonary function test improved after GM-CSF inhalation therapy over 12 months. GM-CSF therapy is an effectivetreatment modality for PAP.

표준치료법인 전 폐하세척술에서 효과를 보지 못했던 폐포단백증 환자에서 GM-CSF 흡입법을 이용하여 임상적으로 증상, 폐기능, 흉부단층촬영에서 호전을 보인 증례를 보고하고자 한다.

Keywords

References

  1. Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958;258:1123-1142. https://doi.org/10.1056/NEJM195806052582301
  2. Wang BM, Stern EJ, Schmidt RA, Pierson DJ. Diagnosing pulmonary alveolar proteinosis: a review and an update. Chest 1997;111:460-466. https://doi.org/10.1378/chest.111.2.460
  3. Ramirez J, Schultz RB, Dutton RE. Pulmonary alveolar proteinosis: a new technique and rationale for treatment. Arch Intern Med 1963;112:419-431. https://doi.org/10.1001/archinte.1963.03860030173021
  4. Du Bois RM, McAllister WA, Branthwaite MA. Alveolar proteinosis: diagnosis and treatment over a 10-year period. Thorax 1983;38:360-363. https://doi.org/10.1136/thx.38.5.360
  5. Kariman K, Kylstra JA, Spock A. Pulmonary alveolar proteinosis: prospective clinical experience in 23 patients for 15 years. Lung 1984;162:223-231. https://doi.org/10.1007/BF02715650
  6. Beccaria M, Luisetti M, Rodi G, et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 2004;23:526-531. https://doi.org/10.1183/09031936.04.00102704
  7. Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003;349:2527-2539. https://doi.org/10.1056/NEJMra023226
  8. Ikegami M, Jobe AH, Huffman Reed JA, Whitsett JA. Surfactant metabolic consequences of overexpression of GM-CSF in the epithelium of GM-CSF-deficient mice. Am J Physiol 1997; 273:L709-L714.
  9. Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest 1996;97:649-655. https://doi.org/10.1172/JCI118461
  10. Reed JA, Ikegami M, Cianciolo ER, et al. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol 1999;276:L556-L563.
  11. Venkateshiah SB, Yan TD, Bonfield TL, et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 2006;130:227-237. https://doi.org/10.1378/chest.130.1.227
  12. Wylam ME, Ten R, Prakash UB, Nadrous HF, Clawson ML, Anderson PM. Aerosol granulocyte-macrophage colonystimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006;27:585-593. https://doi.org/10.1183/09031936.06.00058305
  13. Martin RJ, Coalson JJ, Rogers RM, Horton FO, Manous LE. Pulmonary alveolar proteinosis: the diagnosis by segmental lavage. Am Rev Respir Dis 1980;121:819-825.
  14. Kim G, Lee SJ, Lee HP, et al. The clinical characteristics of pulmonary alveolar proteinosis: experience at Seoul National University Hospital, and review of the literature. J Korean Med Sci 1999;14:159-164.
  15. Ramirez J, Nyka W, McLaughlin J. Pulmonary alveolar proteinosis: diagnostic technics and observations. N Engl J Med 1963;268: 165-171. https://doi.org/10.1056/NEJM196301242680401
  16. Shah PL, Hansell D, Lawson PR, Reid KB, Morgan C. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax 2000;55:67-77. https://doi.org/10.1136/thorax.55.1.67
  17. Kitamura T, Uchida K, Tanaka N, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000;162:658-662. https://doi.org/10.1164/ajrccm.162.2.9910032